SCHEMBL3684064

SCHEMBL3684064

Cc1c(S(=O)(=O)Cl)sc2ccc(C(F)(F)F)cc12

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CMA1 P23946 3/20 0.39
KIF11 P52732 2/20 0.39
AKR1B1 P15121 1/20 0.38
PFKFB3 Q16875 5/20 0.37
MIF P14174 1/20 0.37
MCL1 Q07820 1/20 0.36
PFKFB4 Q16877 3/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
G6PD P11413 1/20 0.36
TLR9 Q9NR96 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3684890 0.85 MEN1 (0.43) NPSR1L3MBTL1MEN1KMT2ACMA1
SCHEMBL3687954 0.84 NPSR1 (0.40) NPSR1L3MBTL1MEN1KMT2ACMA1
SCHEMBL3687952 0.84 MEN1 (0.43) NPSR1L3MBTL1MEN1KMT2ACMA1
SCHEMBL788282 0.80 CMA1 (0.48) NPSR1L3MBTL1CMA1AKR1B1PFKFB3
SCHEMBL788031 0.80 NPSR1 (0.52) NPSR1L3MBTL1CMA1AKR1B1PFKFB3
SCHEMBL337593 0.78 NPSR1 (0.62) NPSR1L3MBTL1CMA1AKR1B1PFKFB3
SCHEMBL13508383 0.78 CA1 (0.44) NPSR1L3MBTL1CMA1PFKFB3PFKFB4
SCHEMBL787935 0.77 PFKFB3 (0.50) NPSR1L3MBTL1CMA1AKR1B1PFKFB3
SCHEMBL787547 0.75 L3MBTL1 (0.50) NPSR1L3MBTL1MEN1KMT2ACMA1
SCHEMBL788489 0.75 PFKFB3 (0.54) NPSR1L3MBTL1CMA1AKR1B1PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG NPSR1 466/4885L3MBTL1 4653/4885MEN1 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.